Panacea Biotec Ltd. — Interim / Quarterly Report 2026

Aug 14, 2025

==> picture [149 x 76] intentionally omitted <==

August 14, 2025

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: (1) Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter ended 30.06.2025

• (2) (i) Date, time and venue of 41[st] AGM - Tuesday, 30.09.2025 at 11:30 A.M.; and (ii) Dates of Book Closure - 26.09.2025 to 30.09.2025

Ref: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In continuation to our letter dated August 04, 2025, and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you that:

1. The Board of Directors has at its meeting held today, i.e. August 14, 2025, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended June 30, 2025. The same was also reviewed by the Audit Committee in its meeting held on August 13, 2025. A copy of the said results along with the Limited Review Report is enclosed as Annexure - A .

Pursuant to Regulation 46(2)(l) of the SEBI LODR Regulations, the aforesaid statements of financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com.

Further, pursuant to Regulation 47(1)(b) of the SEBI LODR Regulations, the Quick Response Code and the details of the webpage where complete financial results of the Company for the quarter ended June 30, 2025, are accessible to the Investors, is being sent for publication in newspapers.

Vinod Goel

Digitally signed by Vinod Goel Date: 2025.08.14 17:32:24 +05'30'

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com

==> picture [149 x 76] intentionally omitted <==

1. The Board of Directors has also decided that:

2. i) the 41[st] Annual General Meeting of the Company will be held on Tuesday, September 30, 2025 at 11:30 A.M. through Video Conferencing / Other Audio-Visual Means; and

3. ii) the Register of Members and Share Transfer Books will remain closed from Friday, September 26, 2025, to Tuesday, September 30, 2025 (both days inclusive) for the purpose of Annual General Meeting.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 04:45 P.M. This is for your information and records please.

Thanking you Sincerely yours, for Panacea Biotec Limited

Vinod Digitally signed by Vinod Goel Goel Date: 2025.08.14 17:32:51 +05'30'

Vinod Goel

Group CFO and Head Legal & Company Secretary

Encls: As above

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com

(� in Lakh except per share)

f' IPanacea Biotec lr\nov,1tto" In . uoport ot l1f(	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025	Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025
Particulars	Standalone				Consolidated
	Quarter Ended			Year Ended	Quarter Ended			Year Ended
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	June 30, **2025 **	March 31, **2025 **	June 30, 2024	March 31, 2025
	(Unaudited)	Audited (Refer note 3)	(Unaudited)	(Audited)	(Unaudited)	Audited (Refer note 3)	(Unaudited)	(Audited)
Total income from operations	11,225	6,790	5,688	30,985	16,670	13,253	11,572	55,909
Net Profit /(Loss)for theperiod/year(before tax,exceptional and/or extraordinaritem)	(884)	(2,203)	(1,498)	(2,606)	(476)	(2,775)	(1,979)	(4,394)
Net Proft /(Loss)for theperiod/year befre tax(afer exceptional and/or extraordinaritem)	(884)	(2,203)	(1,498)	(2,606)	656	(4)	(1,705)	(795)
Net Profit /(Loss)for theperiod/year afer tax(afer exceptional and/or extraordinaryitem)	(670)	(1,239)	(1,378)	(1,523)	396	(199)	(1,588)	(872)
Total comprehensive income/(loss) for the period/year (comprising of profit(loss) for the period/year(afer tax)and other comprehensive income(afer tax))	(668)	(1,229) 613	(1,378) 613	(1,518) 613	394 613	(63) 613	(1,585) 613	(761)
EquitShare Capital(face value of� 1per share)	613							613
Eaming/(loss) per equity share, (annualised, except for quarters): Basic and Diluted	(1.09)	(2.02)	(2.25)	(2.49)	0.66	(0.31)	(2.59)	(1.37)

Notes:

• I The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchanges websites, NSE- http://www.nseindia.com, BSE- http://www.bseindia.com and is also available on the Company's website, http://www.panaceabiotec.com.

• 2 The said financial results for the Quarter Ended June 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 13, 2025 and August 14, 2025 respectively and have been approved by the statutory auditors of the Company.

• 3 Amounts for the quarters ended March 3 J, 2025 represent the balancing amounts between the audited amounts for the full financial year and published year to date amounts upto the third quarter of the respective financial years, which had been subjected only to limited review.

• 4 The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("Ind-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

• 5 Previous period / year amounts have been regrouped/ reclassi tied to make them comparable with those of current period/ year.

==> picture [191 x 19] intentionally omitted <==

----- Start of picture text -----

Place: New Delhi
I
Date: August 14, 2025
----- End of picture text -----

==> picture [76 x 77] intentionally omitted <==

==> picture [169 x 96] intentionally omitted <==

----- Start of picture text -----

For and on behalf of the Board of Directors of
Panacea Biotec Limited
Dr. Rajesh Jain
Chairman & Managing Director
�-
----- End of picture text -----

Panacea Biotec Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab CIN: L33 l l 7PB I 984PLC022350 - Ph. No. 91-11-4 I 679000, Fax: 91-11-4 I 679070, Website: https://www.panacea-biotec.com, E-mail: Corporate@panaceabiotec.com

. ..

�\ /Panacea Biotec lnnov.t1c,11 •n •,ur,pnrr nf lit<•	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)	Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June JO, 2025 (fin Lakh except per share)
S.No Particulars I Income: a) Revenue from operations b) Other income Total Income II Expenditure: a) Cost of raw and packing materials consumed b) Purchase of traded goods c) Changes in inventories of finished goods, traded goods and work-in-progress d) Employee benefits expense e) Finance cost t) Depreciation and amorisation expense g) Other expenses Total expenses IllProfit/(loss) before tax and exceptional item (1-11) IV Exceptional items (refer note 5) VProfit/(loss) before tax (lll+IV) VITax expense: a) Current tax (net) b) Deferred tax charge/(created) (refr note 6) Total tax expenses VIINet Profit/(loss) after tax for the period/year (V-VJ) VIIIProfit/(loss) for the period/year attributable to: i) Owners of the Company ii) Non-controlling interest IXOther comprehensive income/(loss): a) i) Items that will not be reclassified to profit or loss ii) Income tax related to above b) i) Items that will be reclassified to profit or loss ii) Income tax related to above XTotal comprehensive income/(loss) for the period/year (VII+IX) XITotal comprehensive income/(loss) attributable to: i) Owners of the Company ii) Non-controlling interest XIIPaid-up equity share capital (face value of�I/- each) XIIIOther equity XIVEarning/(loss) per equity share (annualised, except for quarters) Basic and Diluted ( in �)	Standalone				Consolidated
	Quarter Ended June JO, March JI, June JO, 2025 2025 2024 (Unaudited) Audited (Unaudited) (Refer note 7)			Year Ended March 31, 2025 (Audited)	Quarter Ended June JO, March 31, June JO, 2025 2025 2024 Unaudited Audited (Unaudited) (Refer note 7)				Year Ended
									March 31, 2025 (Audited)
	11,225 495 11,720 6,094 114 6 2,537 600 477 2,776 12,604 (884) - (884) - (214) (214) (670) (670) - 2 - - - (668) (668) - 613 - (109)	6,790 609 7,399 5,937 175 (3,410) 2,726 464 491 3,219 9,602 (2,203) - (2,203) - (964) (964) (1,239) (1,239) - 13 (3) - - (1,229) (1,229) - 613 - (2.02)	5,688 30,985 380 1,662 6,068 32,647 1,444 12,401 - 175 522 (2,306) 2,153 9,702 321 1,546 508 2,029 2,618 11,706 7,566 35,253 (1,498) (2,606) - - (1,498) (2,606) - - (120) (1,083) (120) (1,083) (1,378) (1,523) (1,378) (1,523) - - - 7 - (2) - - - - (1,378) (1,518) (1,378) (1,518) - - 613 613 - 30,784 (2.25) (2.49)		16,670 567 17,237 7,271 201 250 4,572 86 839 4,494 17,713 (476) 1,132 656 - 260 260 396 405 (9) (3) I - - 394 403 (9) 613 - 0.66	13,253 859 14,112 8,332 745 (3,869) 4,913 104 842 5,820 16,887 (2,775) 2,771 (4) I 194 195 (199) (189) ( 10) 26 (7) 117 - (63) (53) (10) 613 - (0.31)	11,572 380 11,952 4,024 - 148 3,750 87 873 5,049 13,931 (1,979) 274 (1,705) - ( 117) (117) (1,588) (1,580) (8) ( I 0) 3 10 - (1,585) (1,577) (8) 613 - (2.59)		55,909 2,066 57,975 21,407 760 (2,213) 17,305 388 3,481 21,241 62,369 (4,394) 3,599 (795) I 76 77 (872) (837) (35) (8) 2 117 - (761) (726) (35) 613 82,866 ( 1.3 7)

		Statement of Standalone and Consolidated Financial Results(Unaudited) for theQuarter Ended June JO, 2025
		Unaudited Se2ment-wise Revenue, Results and Capital Employed
							(fin Lakh)
		Particulars		Consolidated
				Quarter Ended			Consolidated
				June JO, 2025	March JI, June JO, 2025 2024		March 31, 2025
	a) Segment revenue (i) Vaccines (ii) Formulations Sub total Less: Inter segment revenue Total se2ment revenue b) Segment results Profit(+)/ loss(-) before tax (i) Vaccines (ii) Formulations Sub total Other unallocated expenditure net of unallocatedincome and exceptional items Total Profit/(loss) before tax			(Unaudited)	Audited (Unaudited) (Audited) (Refer note 7)
				11,225 5,445 16,670 - 16,670	6,790 5,687 30,984 6,463 5,885 24,925 13,253 11,572 55,909 - - - 13,253 11,572 55,909
				(425) 1,081 656 - 656	(1,885) (1,327) (1,652) 1,881 (378) 857 (4) (1,705) (795) - - - (4) (1,705) (795)
	c) Capital employed Segment assets (i) Vaccines (ii) Fonnulations Sub Total Segment liabilities (i) Vaccines (ii)Formulations Sub Total Capital employed (Segment assets - segment liabilities) (i) Vaccines (ii)Formulations			87,506 40,151	89,119 76,301 89,119 39,856 46,857 39,856
				127,657 31,321 12,672 43,993	128,975 123,158 128,975 35,087 30,484 35,087 10,826 10,241 10,826 45,913 40,72S 45,913
				56,185 27,479	54,032 45,817 29,030 36,616			54,032 29,030
	Total capital employed			83,664	83,062 82,433			83,062

{[nacea Biotec Innovation in support of life

Notes:

1. The financial results for the quarter ended June 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 13, 2025 and August 14, 2025, respectively and have been reviewed by the statutory auditors of the Company.

2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rule, 20 I 5, as amended from time to time, specified under section I 33 of the Companies Act, 2013.

3. The consolidated financial results of the Company have been prepared by consolidating the Company's reviewed financial results for the respective periods with the reviewed financial results of the following wholly owned subsidiaries ("WOS") and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the enterprises hereinafter collectively referred to as "the Group"):

4. (i) Indian WOS: Panacea Biotec Pharma Limited ("PBPL") and Meyten Realtech Private Limited;

5. (ii) Overseas WOS: Panacea Biotec (International) S.A. ("PBS"), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and

6. (iii) Enterprises over which the Company exercises control: PanEra Biotec Private Limited and Adveta Power Private Limited. _considered as a subsidiary for the purpose of consolidation as per Ind AS I 10_

7. For the quarter ended June 30, 2025, the Company has incurred loss (before tax and exceptional items) oH884 lakh (quarter ended June 30, 2024: loss oHl,498 lakh) and the Group has incurred a loss (before tax and exceptional items) of N76 Iakh (quarter ended June 30, 2024: loss of ti ,979 lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis.

8. During the quarter ended June 30, 2025, the Group has recognised an exceptional income oft I, 132 Lakh under the "Exceptional Item" in the consolidated statement of profit and loss, which includes:

9. (i) revenue on 858 lakh (quarter ended June 30, 2024: Nil), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA ("Apotex") to settle the ongoing dispute between Apotex and Company & PBPL; and

10. (ii) revenue of t274 lakh (quarter ended June 30, 2024: t274 lakh), out of the remaining deferred consideration of t2,l l l lakh as at March 31, 2025, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration oft 1,837 lakh (June 30, 2024: t5,436 lakh) would be recognised in subsequent quarters I years and is shown as Contract Liability in the consolidated financial statement of Group.

==> picture [166 x 84] intentionally omitted <==

/ Panacea Biotec 4r Innovation in support oi llfe

1. The standalone financial results for the quarter and year ended March 31, 2025, includes deferred tax created for Rs 416 lakhs on account of adjustments pertaining to earlier years. The consolidated financial results for the quarter and year ended March 31, 2025, includes deferred tax charge for Rs 270 lakhs on account of adjustments pertaining to earlier years.

2. Amounts for the quarter ended March 31, 2025 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only to limited review.

3. l results of the

4. has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financia Group for the quarter ended June 30, 2025.

5. 1. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Jnd AS I 08, 'Operating Segments', the management

6. The necessary certificate / report in respect of the above results in terms of requirement of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 20 I 5, has been placed before the Board of Directors.

7. I 0. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year.

8. '0' under "Rs. in Lakh" represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off.

9. The above results are also available on the Company's website https://www.panaceabiotec.com

Place: New Delhi

Date: August 14, 2025

Panacea Biotec Limited

==> picture [75 x 77] intentionally omitted <==

==> picture [202 x 115] intentionally omitted <==

----- Start of picture text -----

For and on behalf of the Board of Directors of
Panacea Biotec Limited
Dr. Rajesh Jain
Ch� and Manag;ng Dkeeto,
----- End of picture text -----

Regd. Office: Ambala-Chandigarh Highway, Lalru-14050 I, Punjab CIN: L33117PB1984PLC022350, Ph. No. +91-11-41679000, Fax: +91-11-41679070 Website: https://www.panaceabiotec.com, E-mail: corporate@panaceabiotec.com

==> picture [403 x 54] intentionally omitted <==

Suresh Surana & Associates LLP 2nd Floor, Tower-B, B-37 Sector-1, Noida (NCR) – 201301 (UP), India T +91 120 626 5555 newdelhi@ss-associates.com www.ss-associates.com LLP Identity No. AAB-7509

Independent Auditor’s Limited Review Report on Unaudited Standalone Financial Results for the quarter ended on June 30, 2025, of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”)

To The Board of Directors, Panacea Biotec Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Panacea Biotec Limited (the ‘Company’) for the quarter ended June 30, 2025 (hereinafter referred to as “Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“IND AS 34”), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143 (10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under section 133 of Companies Act, 2013 and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

==> picture [576 x 87] intentionally omitted <==

==> picture [403 x 54] intentionally omitted <==

Other Matter

1. The Statement includes comparative figures for the quarter ended June 30, 2024 which have been reviewed by the predecessor Statutory Auditors of the Company, where they have expressed an unmodified conclusion vide their report dated August 14, 2024 on those unaudited standalone financial results.

Our conclusion on the Statement is not modified in respect of the above matter.

For Suresh Surana & Associates LLP

Chartered Accountants ICAI Reg. No. 121750W/W100010

Kapil Kedar Partner Membership No. 094902 UDIN: 25094902BMOJWX8297

Dated: August 14, 2025 Place: Noida

==> picture [231 x 95] intentionally omitted <==

==> picture [403 x 54] intentionally omitted <==

Suresh Surana & Associates LLP 2nd Floor, Tower-B, B-37 Sector-1, Noida (NCR) – 201301 (UP), India T +91 120 626 5555 newdelhi@ss-associates.com www.ss-associates.com LLP Identity No. AAB-7509

Independent Auditor’s Limited Review Report on Unaudited Consolidated Financial Results for the quarter ended on June 30, 2025, of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”)

To The Board of Directors, Panacea Biotec Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Panacea Biotec Limited (“the Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as ‘the Group’), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended June 30, 2025 (hereinafter referred to as “Statement”), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

2. The Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“IND AS 34”), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, to the extent applicable.

==> picture [576 x 88] intentionally omitted <==

==> picture [403 x 63] intentionally omitted <==

1. Based on our review conducted and procedure performed as stated above and based on the consideration of the review reports of other auditors referred in ‘Other Matters’ section below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under section 133 of Companies Act, 2013 and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

1. We did not review the interim financial results of 2 step down subsidiary included in the unaudited consolidated financial results, whose interim financial results reflect total revenue of Rs. 260 Lakh, total net loss after tax and total comprehensive loss of Rs. 268 Lakh for the quarter ended June 30, 2025, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is solely based on the reports of the other auditors and the procedure performed by us as stated in paragraph 3 above.

2. The unaudited consolidated financial results include the interim financial results of 4 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 16 Lakh, total net loss after tax and total comprehensive loss of Rs. 52 Lakh for the quarter ended June 30, 2025, as considered in the unaudited consolidated financial results. These interim financial results have not been reviewed by their auditors and have been furnished to us by the management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

3. The Statement includes comparative figures for the quarter ended June 30, 2024 which have been reviewed by the predecessor Statutory Auditors of the Company, where they have expressed an unmodified conclusion vide their report dated August 14, 2024 on those unaudited consolidated financial results.

Our conclusion on the Statement is not modified in respect of the above matters.

For Suresh Surana & Associates LLP Chartered Accountants ICAI Reg. No. 121750W/W100010

Digitally signed by KAPIL KEDAR DN: cn=KAPIL KEDAR c=IN o=Personal KAPIL KEDAR Reason: I am the author of this document Location: Date: 2025-08-14 14:57+05:30

Kapil Kedar Partner Membership No. 094902 UDIN: 25094902BMOJWY4998

Dated: August 14, 2025 Place: Noida

==> picture [231 x 90] intentionally omitted <==

==> picture [403 x 63] intentionally omitted <==

Independent Auditor’s Limited Review Report on Unaudited Consolidated Financial Results for the Quarter ended on June 30, 2025, of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”)

Annexure 1

List of entities included in the Statement

Name of the Holding Company

• 1) Panacea Biotec Limited

Name of subsidiaries and step-down subsidiaries

• 1) Panacea Biotec Pharma Limited

• 2) Panacea Biotec (International) SA

• 3) Panacea Biotec Germany GmBH (Wholly owned Subsidiary of Panacea Biotec (International) SA)

• 4) PanEra Biotec Private Limited*

• 5) Meyten Realtech Private Limited

• 6) Adveta Power Private Limited*

• 7) Panacea Biotec Inc (Wholly owned subsidiary of Panacea Biotec Pharma Limited) (incorporated on April 09, 2024)

*Enterprises over which the Company exercises control – These entities are considered as a subsidiary for the purpose of consolidation as per Ind AS 110.

==> picture [231 x 90] intentionally omitted <==